期刊文献+

白血病血小板输注无效的危险因素及人类白细胞抗原-Ⅰ抗体、转化生长因子-β1的预测价值

Risk factors of ineffective platelet transfusion for leukemia and the predictive value of HLA-Ⅰantibody and TGF-β1
原文传递
导出
摘要 目的分析白血病血小板输注无效的危险因素,探讨人类白细胞抗原(HLA)-Ⅰ抗体、转化生长因子-β1(TGF-β1)对血小板输注治疗白血病无效的预测价值。方法回顾性分析2020年1月至2023年9月重庆医科大学附属巴南医院108例急性白血病(AL)患者的临床资料。所有患者均行血小板输注治疗,均检测HLA-Ⅰ抗体、TGF-β1表达情况。将受试者根据血小板输注效果分为无效组(38例)和有效组(70例)。比较HLA-Ⅰ抗体及TGF-β1表达水平,采用logistic回归分析AL血小板输注无效的危险因素。绘制受试者工作特征(ROC)曲线分析HLA-Ⅰ抗体、TGF-β1对AL血小板输注无效的预测价值。结果108例患者共输注血小板1575次,血小板输注有效率为68.00%(1071/1575)。Logistic回归结果显示,输血次数>6次、感染、活动性出血、细菌培养阳性、HLA-Ⅰ抗体阳性、输注前低血小板计数、低TGF-β1水平是AL血小板输注无效的危险因素(P<0.05)。ROC曲线分析显示,HLA-Ⅰ抗体、TGF-β1单独及联合预测AL血小板输注无效的AUC分别为0.748、0.712、0.812,灵敏度分别为83.20%、74.30%和93.80%,联合预测效能最高。结论在AL血小板输注治疗中,HLA-Ⅰ抗体及TGF-β1联合检测对输注无效的预测有较高价值。临床可通过针对性的防治方案对存在相关危险因素的患者进行干预,以期进一步改善血小板输注效果。 Objective To analyze the risk factors of ineffective platelet transfusion in leukemia,and explore the predictive value of human leukocyte antigen(HLA)-Ⅰantibody and transforming growth factor-β1(TGF-β1)for ineffective platelet transfusion in leukemia.Methods The clinical data of 108 patients with acute leukemia from January 2020 to September 2023 in Banan Hospital Affiliated to Chongqing Medical University were retrospectively analyzed.All patients were treated with platelet transfusion,and the expression of HLA-Ⅰantibody and TGF-β1 was detected.The subjects were divided into ineffective group(38 cases)and effective group(70 cases)according to the effect of platelet transfusion.The general data,HLA-Ⅰantibody and TGF-β1 of the two groups were compared,and the risk factors of ineffective platelet transfusion in leukemia were analyzed by logistic regression.The receiver operating characteristic(ROC)curve was drawn to analyze the predictive value of HLA-Ⅰantibody and TGF-β1 for ineffective platelet transfusion in leukemia.Results A total of 1575 platelets were transfused in 108 patients,and the effective rate of platelet transfusion was 68.00%(1071/1575).Logistic regression results showed that the number of transfusions>6 times,infection,active bleeding,low positive bacterial culture,positive HLA-Ⅰantibody,platelet count before transfusion,low TGF-β1 level were risk factors affecting the ineffectiveness of platelet transfusion in leukemia patients(P<0.05).ROC curve analysis showed that the AUC of HLA-Ⅰantibody and TGF-β1 a lone and combined predicting the ineffectiveness of platelet transfusion in leukemia patients was 0.748,0.712,0.812,and the sensitivity was 83.20%,74.30%,93.80%,respectively,with the combined prediction being the highest.Conclusion Positive HLA-Ⅰantibodies and low TGF-β1 levels are risk factors for ineffective platelet transfusion in leukemia.Targeted intervention schemes can be used to intervene in patients with the above factors,in order to further improve the effect of platelet transfusion.
作者 晏玲 刘锋 黄鑫 YAN Ling;LIU Feng;HUANG Xin(Department of Blood Transfusion,Banan Hospital Affiliated to Chongqing Medical University,Chongqing 400000,China)
出处 《中国临床研究》 CAS 2024年第11期1730-1734,共5页 Chinese Journal of Clinical Research
关键词 急性白血病 血小板输注 人类白细胞抗原-Ⅰ抗体 转化生长因子-Β1 疗效 危险因素 Leukemia Platelet transfusion Human leukocyte antigenⅠantibody Transforming growth factor-β1 Efficacy Risk factors
  • 相关文献

参考文献7

二级参考文献74

  • 1王晓伟,邵春燕,张菁,任苓苓,卓海龙,骆群.北京地区HPA1-6,15基因库的建立与应用[J].中国实验血液学杂志,2020,28(1):296-299. 被引量:9
  • 2王书春,邹尧,刘晓明,陈晓娟,张丽,杨文钰,刘天峰,郭晔,陈玉梅,竺晓凡.减低剂量环磷酰胺联合环孢菌素A治疗重型再生障碍性贫血患儿的疗效分析[J].中国实验血液学杂志,2020,28(1):225-229. 被引量:11
  • 3廖雪莲,谢晓恬,李本尚,李莉,杨莉莉.血管内皮生长因子对人急性白血病细胞凋亡影响及相关基因表达的临床与实验研究[J].中国当代儿科杂志,2006,8(6):491-495. 被引量:3
  • 4Swerdlow SH, Campo E, Harris NL, et al. World Health Organi- zation Classification of Tumours of Haematopoietie and Lymphoid Tissue [ M ]. 4th ed. Lyon:IARC Press, 2008:194-195.
  • 5Owen RG, Treon SP, A1-Katib A, et al. Clinicopathological definition of Waldenslrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003, 30(2): 110-115.
  • 6Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr6m' s maeroglobulinemia [J]. N Engl J Med, 2012, 367 ( 9 ) :826-833.
  • 7Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia[J]. Blood, 2009, 113 ( 18 ): 4163-4170.
  • 8Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom' s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) [J]. Leuk Res, 2010, 34 ( 10): 1340-1343.
  • 9Kastritis E, Zervas K, Repoussis P, et al. Prognostication inyoung and old patients with Waldenstr6m's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase [J]. Clin Lymphoma Myeloma, 2009, 9( 1 ): 50-52.
  • 10Treon SP. How I treat Waldenstr6m macroglobulinemia [J]. Blood, 2009, 114(12): 2375-2385.

共引文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部